InnoCare Pharma (HKG:9969, SHA:688428) said the 80 mg once daily dose of its BTK inhibitor, Orelabrutinib, for the treatment of relapsing-remitting multiple sclerosis, was selected for phase 3 progressive multiple sclerosis studies following a demonstration of efficacy and safety profile.
The company's phase 2 results were released at the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum. These results will be presented as the on-site poster at the forum on Thursday, a Wednesday bourse filing said.
Orelabrutinib is a selective brain-penetrant BTK inhibitor that inhibits B cell, microglia, and macrophage activation in the central nervous system along with inhibiting macrophage activation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.